Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 October 2023 | Story Dr Kwazi Magwenzi | Photo supplied
SANRAL Chair launch
The SANRAL Chair in Mathematics and Science , Prof Loyiso Jita with the Programme graduates, the PhD and Masters SANRAL Alumni at the event held on 28 September 2023 in Johannesburg, South Africa.

The South African Chapter of the South African National Roads Agency Limited (SANRAL) Chair alumni programme at the University of the Free State (UFS) was recently launched at the Silverstar Hotel and Casino in Johannesburg. The event aimed to showcase and celebrate the achievements made and lessons learnt in the programme, highlight the key elements and outputs to the Faculty of Education stakeholders and reimagine the future. The Faculty of Education has increased its footprint in Engaged Scholarship activities, aligning itself with the UFS Vision 130. Multiple stakeholders and community partners were invited to witness the outstanding achievements of this programme.

Since its inception in 2014, the SANRAL Chair has produced over 40 PhD graduates in three countries, namely South Africa, Lesotho, and Zimbabwe. One of the key goals of Vision 130 is for the UFS to be regionally engaged and to contribute to pressing societal needs. This involves knowledge generation that contributes to local and regional development and building sustainable partnerships. The PhD and Masters graduates have become a highly valued human resource in the South African education system and the region, and are now positioned as leaders in Institutions of higher learning in South Africa, Lesotho, and Zimbabwe.

The SANRAL Chair currently supervises a cohort of doctoral and master's students,  providing guidance in mathematical research and publications. The internship programme represents SANRAL's commitment to building skilled capacity in communities, along with driving social and economic transformation. SANRAL has also identified common challenges faced by Small, Medium, and Micro-sized Enterprises (SMMEs) in its projects and has implemented training programmes to address these issues. 

South Africa has implemented a range of programmes designed to achieve Sustainable Development Goal 1 (SDG 1), which includes land reform, agriculture, free higher education and growth. Despite the significant progress made on South Africa’s developmental journey since the advent of democracy in 1994, the country remains one of the most unequal societies in the world. Achieving the SDGs is, therefore, in South Africa’s best interest as the country pursues the vision of a united, non-racial, non-sexist, and prosperous nation living in harmony with itself and the rest of the world. 

As South Africa looks ahead to 2030, it seeks to build on the substantial progress achieved thus far, and on the robust policy, legislative, and planning foundation. The focus will be on consolidating and expanding the many areas where public welfare and development are at the forefront. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept